PD-1 Knockout Anti-MUC1 CAR-T Cells (Guangzhou Anjie Biomedical)

N/A

Report date: 2024/08/21 17:32:18

Base Information

Drug NamePD-1 Knockout Anti-MUC1 CAR-T Cells (Guangzhou Anjie Biomedical)
Drug Alias NameAJMUC1
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionT lymphocyte replacementsMucin-1 modulators
TargetsMucin-1
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Anjie Biomedical Technology
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Anjie Biomedical Technology
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A